S&P 500 7,498.96 -0.14% NASDAQ 25,690.90 -0.57% DOW 52,218.58 -0.01% R2K 2,959.94 -0.92% VIX 17.70 +6.37% US 10Y 4.66 +0.63% DXY 101.22 +0.08% GOLD 4,088.20 -1.42% CRUDE 90.87 +4.65% BITCOIN 65,578.44 -0.79%

S&P 500 7,498.96 -0.14% NASDAQ 25,690.90 -0.57% DOW 52,218.58 -0.01% R2K 2,959.94 -0.92% VIX 17.70 +6.37% US 10Y 4.66 +0.63% DXY 101.22 +0.08% GOLD 4,088.20 -1.42% CRUDE 90.87 +4.65% BITCOIN 65,578.44 -0.79%

Next Bullish Trade

Sign in

Account

Create free accountFree dashboard, no payment Sign inEmail yourself a login link CoursesYour library & catalog

IKT

Inhibikase Therapeutics, Inc. NCM · IKT

$2.17 -0.06 (-2.69%)

Extended · +1.10σ

+ Compare Open in Sniper

News · IKT

Full news feed →

Pulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

GlobeNewswire Inc. · 64d ago

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc. · 110d ago

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire Inc. · 244d ago

BIK-Datenanalyse zeigt: Die Aufnahme von BNPL-Transaktionsdaten in die Kredithistorie könnte fast jedem zweiten „Thin-file-Kunden“ helfen, seine Kreditwürdigkeit zu verbessern

GlobeNewswire Inc. · 391d ago

Top 10 Small-Cap Stocks to Watch in 2025

Investing.com · 579d ago

Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease

GlobeNewswire Inc. · 765d ago

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

GlobeNewswire Inc. · 777d ago

Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million

GlobeNewswire Inc. · 793d ago

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

GlobeNewswire Inc. · 798d ago

Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement

GlobeNewswire Inc. · 798d ago

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

GlobeNewswire Inc. · 804d ago

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

GlobeNewswire Inc. · 825d ago

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

GlobeNewswire Inc. · 867d ago

HC Wainwright & Co. Maintains Buy Rating for Inhibikase Therapeutics: Here's What You Need To Know

Benzinga · 869d ago

Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro

GlobeNewswire Inc. · 875d ago

Here's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock Now

Zacks Investment Research · 888d ago

New Strong Buy Stocks for February 13th

Zacks Investment Research · 890d ago

Best Momentum Stocks to Buy for February 8th

Zacks Investment Research · 895d ago

Best Momentum Stocks to Buy for January 31st

Zacks Investment Research · 903d ago

Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib

GlobeNewswire Inc. · 905d ago

New Strong Buy Stocks for January 26th

Zacks Investment Research · 909d ago

Inhibikase Therapeutics, Inc. (IKT) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Investment Research · 912d ago

Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli

GlobeNewswire Inc. · 918d ago